Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-02

AUTHORS

Adil Daud, Harriet M Kluger, Razelle Kurzrock, Frauke Schimmoller, Aaron L Weitzman, Thomas A Samuel, Ali H Moussa, Michael S Gordon, Geoffrey I Shapiro

ABSTRACT

BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS). RESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation. CONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted. More... »

PAGES

432

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2016.419

DOI

http://dx.doi.org/10.1038/bjc.2016.419

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048567126

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28103611


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Belgium", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Israel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-met", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Vascular Endothelial Growth Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Skin Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uveal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Withholding Treatment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daud", 
        "givenName": "Adil", 
        "id": "sg:person.01106713311.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106713311.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kluger", 
        "givenName": "Harriet M", 
        "id": "sg:person.01336750727.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurzrock", 
        "givenName": "Razelle", 
        "id": "sg:person.0772022470.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772022470.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Exelixis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428377.d", 
          "name": [
            "Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schimmoller", 
        "givenName": "Frauke", 
        "id": "sg:person.01150411250.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150411250.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Exelixis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428377.d", 
          "name": [
            "Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weitzman", 
        "givenName": "Aaron L", 
        "id": "sg:person.01173210730.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173210730.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cleveland Clinic Florida", 
          "id": "https://www.grid.ac/institutes/grid.418628.1", 
          "name": [
            "Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samuel", 
        "givenName": "Thomas A", 
        "id": "sg:person.01143554436.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143554436.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moussa", 
        "givenName": "Ali H", 
        "id": "sg:person.016216430013.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016216430013.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pinnacle Oncology Hematology", 
          "id": "https://www.grid.ac/institutes/grid.492843.0", 
          "name": [
            "Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gordon", 
        "givenName": "Michael S", 
        "id": "sg:person.0713550751.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dana\u2013Farber Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shapiro", 
        "givenName": "Geoffrey I", 
        "id": "sg:person.0752005421.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1408868", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000859328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2011.421", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002802838", 
          "https://doi.org/10.1038/jid.2011.421"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.02.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002939839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cmr.0000222598.27438.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003133820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.cmr.0000222598.27438.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003133820"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)60868-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003772891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0010770", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004687723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra041245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005930121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.6723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007324791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0895-4356(93)90163-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008750072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/ppo.0b013e3181bd0431", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009285554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1412082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012352031"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2009.01.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012366197"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(14)60958-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012632588"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2014.6096", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012801179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-10-0489", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012978908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.0494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013364059"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1593/neo.111102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017478734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-11-0240", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021811835"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023536940", 
          "https://doi.org/10.1038/nature00766"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-011-0719-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023891155", 
          "https://doi.org/10.1007/s12094-011-0719-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ctrv.2012.01.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024044063"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024843336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms6712", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025893090", 
          "https://doi.org/10.1038/ncomms6712"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-11-0264", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025899139"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-03-0245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026966842"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clindermatol.2012.08.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027903625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027998728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0000000000000242", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027998728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1000584", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028808360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-0776", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028934066"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.32.4145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031276220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-3169", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031380951"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.12.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037621530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canlet.2012.01.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039022477"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1103782", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041864150"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041973162", 
          "https://doi.org/10.1038/sj.bjc.6600919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600919", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041973162", 
          "https://doi.org/10.1038/sj.bjc.6600919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1406037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047704810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048356671", 
          "https://doi.org/10.1038/nrc3205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature10144", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050798018", 
          "https://doi.org/10.1038/nature10144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051449373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1552-4604.1975.tb05919.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052076247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/jid.2011.218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052787397", 
          "https://doi.org/10.1038/jid.2011.218"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053677952", 
          "https://doi.org/10.1038/nature11183"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1538-7445.am2011-3587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063238417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.21037/atm.2016.05.04", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068831922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076575043", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078586743", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.29.15_suppl.3010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083947519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.9502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842822"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.9530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842850"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-02", 
    "datePublishedReg": "2017-02-01", 
    "description": "BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma.\nMETHODS: Patients received cabozantinib 100\u2009mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS).\nRESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation.\nCONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2016.419", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "116"
      }
    ], 
    "name": "Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma", 
    "pagination": "432", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e75db77b0af4e63d8838ea2ff6974a088f9a6c68a35257b7e9bcbfb314090f77"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28103611"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2016.419"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048567126"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2016.419", 
      "https://app.dimensions.ai/details/publication/pub.1048567126"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:53", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000551.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2016419"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2016.419'


 

This table displays all metadata directly associated to this object as RDF triples.

388 TRIPLES      21 PREDICATES      101 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2016.419 schema:about N0390ff1425d74ef2b51b900ae3dfff91
2 N204707c1bb664ae98fb410e8ea7106c8
3 N238a5a425f6d44329495ad4dd735ce34
4 N2452d801739041f89b566c06418d3829
5 N3ad3a020d43a4c73b170f6b3ff61a82e
6 N3c771806e4ab49ad99e7da031b1edb45
7 N59da8c134f6a49ac90a8e8e2bed067cb
8 N74314d3503be480099137583cb82a336
9 N777e8420f5684cce9751ccf26dc5cc0b
10 N7c4cc92326f8470dae201ce503dc9942
11 N7f9659e0233142cea281da799b6a074a
12 N8b228ad7f46c495e9ee4ad9b146c5c9b
13 N91e714c46a614bcbb817db3d9508fc60
14 N9a3db9a17a3e473cb5914e9b265a9b17
15 Nb09dedf56b134662aa34d7815b28e085
16 Nb44f23a8136045c98e20f8897955e44e
17 Nb733af8cb8e8439e8ebb3564b6a32843
18 Nbf16b8f9964b40dc81a0f7f5b45841ff
19 Nc09e9414f74542f1abca56697eb2d45d
20 Ne035b277975a44679c6e9c71484c7bc8
21 Ne671ef0cbed74920b7fbfcc069ebd815
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N72e0e63210224cb5a3df3bfa9add9734
25 schema:citation sg:pub.10.1007/s12094-011-0719-5
26 sg:pub.10.1038/jid.2011.218
27 sg:pub.10.1038/jid.2011.421
28 sg:pub.10.1038/nature00766
29 sg:pub.10.1038/nature10144
30 sg:pub.10.1038/nature11183
31 sg:pub.10.1038/ncomms6712
32 sg:pub.10.1038/nrc3205
33 sg:pub.10.1038/sj.bjc.6600919
34 https://app.dimensions.ai/details/publication/pub.1076575043
35 https://app.dimensions.ai/details/publication/pub.1078586743
36 https://doi.org/10.1001/jama.2014.6096
37 https://doi.org/10.1002/j.1552-4604.1975.tb05919.x
38 https://doi.org/10.1016/0895-4356(93)90163-u
39 https://doi.org/10.1016/j.canlet.2012.01.026
40 https://doi.org/10.1016/j.ccr.2009.01.021
41 https://doi.org/10.1016/j.ccr.2009.02.007
42 https://doi.org/10.1016/j.clindermatol.2012.08.013
43 https://doi.org/10.1016/j.ctrv.2012.01.002
44 https://doi.org/10.1016/j.ejca.2008.12.015
45 https://doi.org/10.1016/s0140-6736(12)60868-x
46 https://doi.org/10.1016/s0140-6736(14)60958-2
47 https://doi.org/10.1056/nejmoa1000584
48 https://doi.org/10.1056/nejmoa1003466
49 https://doi.org/10.1056/nejmoa1103782
50 https://doi.org/10.1056/nejmoa1112302
51 https://doi.org/10.1056/nejmoa1406037
52 https://doi.org/10.1056/nejmoa1408868
53 https://doi.org/10.1056/nejmoa1412082
54 https://doi.org/10.1056/nejmoa1504030
55 https://doi.org/10.1056/nejmra041245
56 https://doi.org/10.1093/jnci/92.3.205
57 https://doi.org/10.1097/01.cmr.0000222598.27438.82
58 https://doi.org/10.1097/cmr.0000000000000242
59 https://doi.org/10.1097/ppo.0b013e3181bd0431
60 https://doi.org/10.1158/0008-5472.can-03-0245
61 https://doi.org/10.1158/0008-5472.can-10-0489
62 https://doi.org/10.1158/1078-0432.ccr-06-0776
63 https://doi.org/10.1158/1078-0432.ccr-10-3169
64 https://doi.org/10.1158/1535-7163.mct-11-0264
65 https://doi.org/10.1158/1538-7445.am2011-3587
66 https://doi.org/10.1158/2159-8290.cd-11-0240
67 https://doi.org/10.1200/jco.2005.03.6723
68 https://doi.org/10.1200/jco.2010.32.4145
69 https://doi.org/10.1200/jco.2011.29.15_suppl.3010
70 https://doi.org/10.1200/jco.2012.45.0494
71 https://doi.org/10.1200/jco.2016.34.15_suppl.9502
72 https://doi.org/10.1200/jco.2016.34.15_suppl.9530
73 https://doi.org/10.1371/journal.pone.0010770
74 https://doi.org/10.1593/neo.111102
75 https://doi.org/10.21037/atm.2016.05.04
76 schema:datePublished 2017-02
77 schema:datePublishedReg 2017-02-01
78 schema:description BACKGROUND: A phase II randomised discontinuation trial assessed cabozantinib (XL184), an orally bioavailable inhibitor of tyrosine kinases including VEGF receptors, MET, and AXL, in a cohort of patients with metastatic melanoma. METHODS: Patients received cabozantinib 100 mg daily during a 12-week lead-in. Patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumours (RECIST) at week 12 were randomised to cabozantinib or placebo. Primary endpoints were objective response rate (ORR) at week 12 and postrandomisation progression-free survival (PFS). RESULTS: Seventy-seven patients were enroled (62% cutaneous, 30% uveal, and 8% mucosal). At week 12, the ORR was 5%; 39% of patients had SD. During the lead-in phase, reduction in target lesions from baseline was seen in 55% of evaluable patients overall and in 59% of evaluable patients with uveal melanoma. Median PFS after randomisation was 4.1 months with cabozantinib and 2.8 months with placebo (hazard ratio of 0.59; P=0.284). Median PFS from study day 1 was 3.8 months, 6-month PFS was 33%, and median overall survival was 9.4 months. The most common grade 3/4 adverse events were fatigue (14%), hypertension (10%), and abdominal pain (8%). One treatment-related death was reported from peritonitis due to diverticular perforation. CONCLUSIONS: Cabozantinib has clinical activity in patients with metastatic melanoma, including uveal melanoma. Further clinical investigation is warranted.
79 schema:genre research_article
80 schema:inLanguage en
81 schema:isAccessibleForFree true
82 schema:isPartOf N15188cf890664641b62eee665c0473fb
83 Ndc3799afffe14db49c8727c9881a927f
84 sg:journal.1017082
85 schema:name Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
86 schema:pagination 432
87 schema:productId N76bddc7fba42459480dadd65e1c66c39
88 N84dd934f3b32497a9d1d2b80090c20ae
89 N8585c8ae6b44425fa2b9a569fde304e0
90 Nc1afb68c9e2449758981df84694b636f
91 Ncd1731639d45419f95eb6ddc15914a6b
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048567126
93 https://doi.org/10.1038/bjc.2016.419
94 schema:sdDatePublished 2019-04-10T20:53
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nd5dbc6433092496ebb875adadf5b47dd
97 schema:url https://www.nature.com/articles/bjc2016419
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N0390ff1425d74ef2b51b900ae3dfff91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Neoplasm Metastasis
103 rdf:type schema:DefinedTerm
104 N076c7f40f36b4dfcbe4253133211de69 rdf:first sg:person.016216430013.43
105 rdf:rest N371850b84b17416e92b9968674182d2d
106 N07912c8c50ca446ab4f7e872fa6e41c5 rdf:first sg:person.01143554436.02
107 rdf:rest N076c7f40f36b4dfcbe4253133211de69
108 N15188cf890664641b62eee665c0473fb schema:issueNumber 4
109 rdf:type schema:PublicationIssue
110 N204707c1bb664ae98fb410e8ea7106c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name United States
112 rdf:type schema:DefinedTerm
113 N238a5a425f6d44329495ad4dd735ce34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Uveal Neoplasms
115 rdf:type schema:DefinedTerm
116 N2452d801739041f89b566c06418d3829 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Israel
118 rdf:type schema:DefinedTerm
119 N371850b84b17416e92b9968674182d2d rdf:first sg:person.0713550751.04
120 rdf:rest N8af4c260107647e18c89ba09052fbe1c
121 N3ad3a020d43a4c73b170f6b3ff61a82e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Skin Neoplasms
123 rdf:type schema:DefinedTerm
124 N3c771806e4ab49ad99e7da031b1edb45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Antineoplastic Agents
126 rdf:type schema:DefinedTerm
127 N59da8c134f6a49ac90a8e8e2bed067cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Middle Aged
129 rdf:type schema:DefinedTerm
130 N665b19e2ddc649efbe9e25fad883e0d0 schema:name Cancer Care Associates, 1810 E 15th Street, Tulsa, OK 74104, USA
131 rdf:type schema:Organization
132 N72e0e63210224cb5a3df3bfa9add9734 rdf:first sg:person.01106713311.45
133 rdf:rest N7be8282dda2e42ee9fe6f67f3532054a
134 N74314d3503be480099137583cb82a336 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Pyridines
136 rdf:type schema:DefinedTerm
137 N76bddc7fba42459480dadd65e1c66c39 schema:name readcube_id
138 schema:value e75db77b0af4e63d8838ea2ff6974a088f9a6c68a35257b7e9bcbfb314090f77
139 rdf:type schema:PropertyValue
140 N777e8420f5684cce9751ccf26dc5cc0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Aged, 80 and over
142 rdf:type schema:DefinedTerm
143 N78170c30d018483dab30598080393c4b schema:name University of California, San Diego Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658, USA
144 rdf:type schema:Organization
145 N7826cacce3684b56a923d040b719c618 rdf:first sg:person.01150411250.57
146 rdf:rest Ne29b4e46345d4f6bbdb3b2cfddb3e82c
147 N7be8282dda2e42ee9fe6f67f3532054a rdf:first sg:person.01336750727.45
148 rdf:rest Nb4a142e0da6d43f69a9cb0fee47d49e5
149 N7c4cc92326f8470dae201ce503dc9942 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Withholding Treatment
151 rdf:type schema:DefinedTerm
152 N7f9659e0233142cea281da799b6a074a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Male
154 rdf:type schema:DefinedTerm
155 N84dd934f3b32497a9d1d2b80090c20ae schema:name pubmed_id
156 schema:value 28103611
157 rdf:type schema:PropertyValue
158 N8585c8ae6b44425fa2b9a569fde304e0 schema:name dimensions_id
159 schema:value pub.1048567126
160 rdf:type schema:PropertyValue
161 N8af4c260107647e18c89ba09052fbe1c rdf:first sg:person.0752005421.01
162 rdf:rest rdf:nil
163 N8b228ad7f46c495e9ee4ad9b146c5c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Aged
165 rdf:type schema:DefinedTerm
166 N91e714c46a614bcbb817db3d9508fc60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Adult
168 rdf:type schema:DefinedTerm
169 N9a3db9a17a3e473cb5914e9b265a9b17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Humans
171 rdf:type schema:DefinedTerm
172 Nb09dedf56b134662aa34d7815b28e085 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Proto-Oncogene Proteins c-met
174 rdf:type schema:DefinedTerm
175 Nb44f23a8136045c98e20f8897955e44e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Anilides
177 rdf:type schema:DefinedTerm
178 Nb4a142e0da6d43f69a9cb0fee47d49e5 rdf:first sg:person.0772022470.64
179 rdf:rest N7826cacce3684b56a923d040b719c618
180 Nb733af8cb8e8439e8ebb3564b6a32843 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Receptors, Vascular Endothelial Growth Factor
182 rdf:type schema:DefinedTerm
183 Nbf16b8f9964b40dc81a0f7f5b45841ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Belgium
185 rdf:type schema:DefinedTerm
186 Nc09e9414f74542f1abca56697eb2d45d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Melanoma
188 rdf:type schema:DefinedTerm
189 Nc1afb68c9e2449758981df84694b636f schema:name nlm_unique_id
190 schema:value 0370635
191 rdf:type schema:PropertyValue
192 Ncd1731639d45419f95eb6ddc15914a6b schema:name doi
193 schema:value 10.1038/bjc.2016.419
194 rdf:type schema:PropertyValue
195 Nd5dbc6433092496ebb875adadf5b47dd schema:name Springer Nature - SN SciGraph project
196 rdf:type schema:Organization
197 Ndc3799afffe14db49c8727c9881a927f schema:volumeNumber 116
198 rdf:type schema:PublicationVolume
199 Ne035b277975a44679c6e9c71484c7bc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Survival Analysis
201 rdf:type schema:DefinedTerm
202 Ne29b4e46345d4f6bbdb3b2cfddb3e82c rdf:first sg:person.01173210730.54
203 rdf:rest N07912c8c50ca446ab4f7e872fa6e41c5
204 Ne671ef0cbed74920b7fbfcc069ebd815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Female
206 rdf:type schema:DefinedTerm
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:journal.1017082 schema:issn 0007-0920
214 1532-1827
215 schema:name British Journal of Cancer
216 rdf:type schema:Periodical
217 sg:person.01106713311.45 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
218 schema:familyName Daud
219 schema:givenName Adil
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106713311.45
221 rdf:type schema:Person
222 sg:person.01143554436.02 schema:affiliation https://www.grid.ac/institutes/grid.418628.1
223 schema:familyName Samuel
224 schema:givenName Thomas A
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143554436.02
226 rdf:type schema:Person
227 sg:person.01150411250.57 schema:affiliation https://www.grid.ac/institutes/grid.428377.d
228 schema:familyName Schimmoller
229 schema:givenName Frauke
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150411250.57
231 rdf:type schema:Person
232 sg:person.01173210730.54 schema:affiliation https://www.grid.ac/institutes/grid.428377.d
233 schema:familyName Weitzman
234 schema:givenName Aaron L
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173210730.54
236 rdf:type schema:Person
237 sg:person.01336750727.45 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
238 schema:familyName Kluger
239 schema:givenName Harriet M
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336750727.45
241 rdf:type schema:Person
242 sg:person.016216430013.43 schema:affiliation N665b19e2ddc649efbe9e25fad883e0d0
243 schema:familyName Moussa
244 schema:givenName Ali H
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016216430013.43
246 rdf:type schema:Person
247 sg:person.0713550751.04 schema:affiliation https://www.grid.ac/institutes/grid.492843.0
248 schema:familyName Gordon
249 schema:givenName Michael S
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713550751.04
251 rdf:type schema:Person
252 sg:person.0752005421.01 schema:affiliation https://www.grid.ac/institutes/grid.65499.37
253 schema:familyName Shapiro
254 schema:givenName Geoffrey I
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01
256 rdf:type schema:Person
257 sg:person.0772022470.64 schema:affiliation N78170c30d018483dab30598080393c4b
258 schema:familyName Kurzrock
259 schema:givenName Razelle
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772022470.64
261 rdf:type schema:Person
262 sg:pub.10.1007/s12094-011-0719-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023891155
263 https://doi.org/10.1007/s12094-011-0719-5
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/jid.2011.218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052787397
266 https://doi.org/10.1038/jid.2011.218
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/jid.2011.421 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002802838
269 https://doi.org/10.1038/jid.2011.421
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/nature00766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023536940
272 https://doi.org/10.1038/nature00766
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/nature10144 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050798018
275 https://doi.org/10.1038/nature10144
276 rdf:type schema:CreativeWork
277 sg:pub.10.1038/nature11183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053677952
278 https://doi.org/10.1038/nature11183
279 rdf:type schema:CreativeWork
280 sg:pub.10.1038/ncomms6712 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025893090
281 https://doi.org/10.1038/ncomms6712
282 rdf:type schema:CreativeWork
283 sg:pub.10.1038/nrc3205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048356671
284 https://doi.org/10.1038/nrc3205
285 rdf:type schema:CreativeWork
286 sg:pub.10.1038/sj.bjc.6600919 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041973162
287 https://doi.org/10.1038/sj.bjc.6600919
288 rdf:type schema:CreativeWork
289 https://app.dimensions.ai/details/publication/pub.1076575043 schema:CreativeWork
290 https://app.dimensions.ai/details/publication/pub.1078586743 schema:CreativeWork
291 https://doi.org/10.1001/jama.2014.6096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012801179
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1002/j.1552-4604.1975.tb05919.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052076247
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1016/0895-4356(93)90163-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1008750072
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1016/j.canlet.2012.01.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039022477
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1016/j.ccr.2009.01.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012366197
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1016/j.ccr.2009.02.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002939839
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1016/j.clindermatol.2012.08.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027903625
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1016/j.ctrv.2012.01.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024044063
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1016/j.ejca.2008.12.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037621530
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1016/s0140-6736(12)60868-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003772891
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1016/s0140-6736(14)60958-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012632588
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1056/nejmoa1000584 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028808360
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1056/nejmoa1103782 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041864150
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1056/nejmoa1112302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051449373
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1056/nejmoa1406037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047704810
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1056/nejmoa1408868 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000859328
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1056/nejmoa1412082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012352031
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1056/nejmoa1504030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024843336
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1056/nejmra041245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005930121
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1097/01.cmr.0000222598.27438.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003133820
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1097/cmr.0000000000000242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027998728
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1097/ppo.0b013e3181bd0431 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009285554
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1158/0008-5472.can-03-0245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026966842
340 rdf:type schema:CreativeWork
341 https://doi.org/10.1158/0008-5472.can-10-0489 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012978908
342 rdf:type schema:CreativeWork
343 https://doi.org/10.1158/1078-0432.ccr-06-0776 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028934066
344 rdf:type schema:CreativeWork
345 https://doi.org/10.1158/1078-0432.ccr-10-3169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031380951
346 rdf:type schema:CreativeWork
347 https://doi.org/10.1158/1535-7163.mct-11-0264 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025899139
348 rdf:type schema:CreativeWork
349 https://doi.org/10.1158/1538-7445.am2011-3587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063238417
350 rdf:type schema:CreativeWork
351 https://doi.org/10.1158/2159-8290.cd-11-0240 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021811835
352 rdf:type schema:CreativeWork
353 https://doi.org/10.1200/jco.2005.03.6723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007324791
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1200/jco.2010.32.4145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031276220
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1200/jco.2011.29.15_suppl.3010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083947519
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1200/jco.2012.45.0494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013364059
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1200/jco.2016.34.15_suppl.9502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842822
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1200/jco.2016.34.15_suppl.9530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842850
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1371/journal.pone.0010770 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004687723
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1593/neo.111102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017478734
368 rdf:type schema:CreativeWork
369 https://doi.org/10.21037/atm.2016.05.04 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068831922
370 rdf:type schema:CreativeWork
371 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
372 schema:name University of California, San Francisco Medical Center at Parnassus, 1600 Divisadero Street, MZ Bldg A, San Francisco, CA 94115, USA
373 rdf:type schema:Organization
374 https://www.grid.ac/institutes/grid.418628.1 schema:alternateName Cleveland Clinic Florida
375 schema:name Department of Hematology/Oncology, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd, Weston, FL 33331, USA
376 rdf:type schema:Organization
377 https://www.grid.ac/institutes/grid.428377.d schema:alternateName Exelixis (United States)
378 schema:name Exelixis Inc., 210 E. Grand Avenue, South San Francisco, CA 94080, USA
379 rdf:type schema:Organization
380 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
381 schema:name Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028, USA
382 rdf:type schema:Organization
383 https://www.grid.ac/institutes/grid.492843.0 schema:alternateName Pinnacle Oncology Hematology
384 schema:name Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, Scottsdale, AZ 85258, USA
385 rdf:type schema:Organization
386 https://www.grid.ac/institutes/grid.65499.37 schema:alternateName Dana–Farber Cancer Institute
387 schema:name Department of Medical Oncology, Dana-Farber Cancer Institute, Early Drug Development Center, 450 Brookline Avenue, Boston, MA 02215, USA
388 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...